<DOC>
	<DOCNO>NCT02825394</DOCNO>
	<brief_summary>The investigator study aims test correlation Cascade Abrazo point-of-care testing ( POCT ) device ( Helena Laboratories , USA ) plasma level apixaban , dabigatran rivaroxaban , determine diagnostic accuracy POCT rule detect relevant level non-vitamin K antagonist oral anticoagulant ( NOAC ) real-life patient .</brief_summary>
	<brief_title>Specific PoC Testing Coagulation Patients Treated With NOAC 1</brief_title>
	<detailed_description />
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Part A : plan initiation treatment apixaban , dabigatran rivaroxaban Part B : ongoing treatment apixaban , dabigatran rivaroxaban Age ≥ 18 year Written inform consent patient Part A : intake vitamin K antagonists nonvitamin K antagonist oral anticoagulant ( NOAC ) ≤ 14 day prior study participation Part B : intake vitamin K antagonists different NOAC ≤ 14 day prior study participation Intake unfractionated heparin ≤ 12 hour , lowmolecularweight heparin ≤ 24h , heparinoids ( e.g . fondaparinux ) ≤ 72h , direct thrombin inhibitor dabigatran ≤ 72h prior study participation Part A : abnormal routine coagulation test value baseline ( define INR &gt; 1.2 , Quick &lt; 70 % aPTT &gt; 40 sec ) History coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>